Literature DB >> 26913702

Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area.

Seung Bum Lee1, Kang Mo Kim1, Jihyun An1, Danbi Lee1, Ju Hyun Shim1, Young-Suk Lim1, Han Chu Lee1, Young-Hwa Chung1, Yung Sang Lee1.   

Abstract

BACKGROUND & AIMS: We investigated potential aetiologies, clinical characteristics and prognosis of non-B non-C (NBNC) hepatocellular carcinoma (HCC) patients in hepatitis B virus (HBV) endemic area, according to potential causes such as previous HBV exposure, chronic alcohol intake and metabolic syndrome. PATIENTS AND METHODS: Among 4690 HCC patients treated at Asan Medical Center between 2007 and 2009, 523 were newly diagnosed with NBNC HCC, and their medical records and survival data were analyzed retrospectively.
RESULTS: Among 321 NBNC HCC patients whose hepatitis B core antibody (anti-HBc) test results were available, 81.0%, 37.1% and 15.5% had anti-HBc positivity, chronic alcohol intake and metabolic syndrome respectively. One-hundred and fifty-two patients (47.4%) had previous exposure to HBV without chronic alcohol intake or metabolic syndrome. Hepatitis B surface antibody (anti-HBs) was positive in 48.0% of the 523 NBNC HCC patients, which was much lower than that in general Korean population, and 52.3% of anti-HBc-positive NBNC HCC patients were negative for anti-HBs. Anti-HBc-negative alcoholic patients presented with more advanced cirrhosis with Child-Pugh class B/C liver function than anti-HBc-positive patients (P = 0.002). In multivariate analysis, baseline liver function, alpha-foetoprotein levels and tumour stage were significant prognostic factors and aetiology did not affect patient survival.
CONCLUSIONS: Prior HBV infection could be a potential aetiology in over 40% of NBNC HCC patients in HBV endemic area. Positivity for anti-HBc and negativity for anti-HBs may be a serologic surrogate marker for occult HBV infection in these area. The prognosis of NBNC HCC was determined by tumour stage and underlying liver function.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  aetiology; clinical features; hepatitis B virus core antibody IgG; non-B non-C hepatocellular carcinoma; occult hepatitis B virus infection

Mesh:

Substances:

Year:  2016        PMID: 26913702     DOI: 10.1111/liv.13099

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

Review 1.  Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.

Authors:  Tiffany Wu; Ryan M Kwok; Tram T Tran
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

2.  Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma.

Authors:  Shan-Shan Wu; Quan-Yuan Shan; Wen-Xuan Xie; Bin Chen; Yang Huang; Yu Guo; Xiao-Yan Xie; Ming-De Lu; Bao-Gang Peng; Ming Kuang; Shun-Li Shen; Wei Wang
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

3.  Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study.

Authors:  Te-Sheng Chang; Nien-Tzu Hsu; Shu-Chuan Chen; I-Lin Hsu; Mei-Hsuan Lee; Sheng-Nan Lu
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

Review 4.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

5.  Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B.

Authors:  Shiu-Feng Huang; Il-Chi Chang; Chih-Chen Hong; Tseng-Chang Yen; Chao-Long Chen; Cheng-Chung Wu; Cheng-Chung Tsai; Ming-Chih Ho; Wei-Chen Lee; Hsien-Chung Yu; Ying-Ying Shen; Hock-Liew Eng; John Wang; Hui-Hwa Tseng; Yung-Ming Jeng; Chau-Ting Yeh; Chi-Ling Chen; Pei-Jer Chen; Yun-Fan Liaw
Journal:  Hepatol Commun       Date:  2018-04-18

6.  Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea.

Authors:  Jihye Kim; Wonseok Kang; Dong Hyun Sinn; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Korean J Intern Med       Date:  2019-06-17       Impact factor: 2.884

7.  Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.

Authors:  Yen-Po Lin; Pei-Ming Wang; Ching-Hui Chuang; Chee-Chen Yong; Yueh-Wei Liu; Pao-Yuan Huang; Chih-Chien Yao; Ming-Chao Tsai
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

8.  Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir.

Authors:  Seung Bum Lee; Joonho Jeong; Jae Ho Park; Seok Won Jung; In Du Jeong; Sung-Jo Bang; Jung Woo Shin; Bo Ryung Park; Eun Ji Park; Neung Hwa Park
Journal:  Clin Mol Hepatol       Date:  2020-05-29

9.  Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus.

Authors:  Hae Lim Lee; Si Hyun Bae; Jaejun Lee; Pil Soo Sung; Sung Won Lee; Jeong Won Jang; Jungmin Lee; Jong Young Choi; Nam Ik Han; Seung Kew Yoon
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.